Leerink Partners Adjusts Quest Diagnostics Price Target to $154 From $151, Maintains Market Perform Rating
BofA Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating, Maintains Target Price $150
Buy Rating Affirmed for Quest Diagnostics Amid Strong Q2 Financials and Upbeat 2024 Guidance
Quest Diagnostics Analyst Ratings
Truist Securities Adjusts Price Target on Quest Diagnostics to $158 From $150, Maintains Hold Rating
Citi Upgrades Illumina, Quest, Agilent to Buy, Downgrades Avantor
Quest Diagnostics Analyst Ratings
Citigroup Upgrades Quest Diagnostics to Buy From Neutral, Adjusts Price Target to $165 From $145
Analysts' Opinions Are Mixed on These Healthcare Stocks: CureVac (CVAC), Insmed (INSM) and Quest Diagnostics (DGX)
Quest Diagnostics Analyst Ratings
Baird Adjusts Price Target on Quest Diagnostics to $153 From $145, Maintains Neutral Rating
Barclays Sticks to Their Hold Rating for Quest Diagnostics (DGX)
Buy Rating Affirmed: Quest Diagnostics' Strategic Acquisition of LifeLabs Poised to Boost Growth and Profitability
Nephron Adjusts Price Target on Quest Diagnostics to $155 From $152
Quest Diagnostics Analyst Ratings
JPMorgan Adjusts Price Target on Quest Diagnostics to $155 From $152
Argus Adjusts Price Target on Quest Diagnostics to $215 From $163, Keeps Buy Rating
Argus Raises Quest Diagnostics' Price Target to $163 From $155
Buy Rating Affirmed for Quest Diagnostics on Strong Earnings Visibility and Growth Prospects
Baird Adjusts Quest Diagnostics' Price Target to $144 From $138